NCT01482260

Brief Summary

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 30, 2011

Completed
1 day until next milestone

Study Start

First participant enrolled

December 1, 2011

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
Last Updated

November 6, 2012

Status Verified

November 1, 2012

Enrollment Period

1 month

First QC Date

November 26, 2011

Last Update Submit

November 5, 2012

Conditions

Study Arms (3)

Primary Cutaneous Malignant Melanoma

Procedure: Biopsy

Cutaneous Malignant Melanoma Metastases

Procedure: Biopsy

Benign Melanocytic Nevi

Procedure: Biopsy

Interventions

BiopsyPROCEDURE

Biopsy

Benign Melanocytic NeviCutaneous Malignant Melanoma MetastasesPrimary Cutaneous Malignant Melanoma

Eligibility Criteria

Age1 Year+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with * Primary Cutaneous Malignant Melanoma * Cutaneous Malignant Melanoma Metastases * Benign Melanocytic Naevi

You may qualify if:

  • Primary Cutaneous Malignant Melanoma
  • Cutaneous Malignant Melanoma Metastases
  • Benign Melanocytic Naevi

You may not qualify if:

  • \- Other Skin Cancer than Primary Cutaneous Malignant Melanoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, 44791, Germany

Location

Related Publications (1)

  • Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013 Jan;351(1):85-98. doi: 10.1007/s00441-012-1514-5. Epub 2012 Oct 31.

Biospecimen

Retention: SAMPLES WITH DNA

skin biopsy

MeSH Terms

Conditions

Melanoma, Cutaneous Malignant

Interventions

Biopsy

Condition Hierarchy (Ancestors)

MelanomaNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

CytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisSpecimen HandlingDiagnostic Techniques, SurgicalSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Falk G Bechara, PD Dr.

    Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

    STUDY DIRECTOR
  • Peter Altmeyer, Prof. Dr.

    Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 26, 2011

First Posted

November 30, 2011

Study Start

December 1, 2011

Primary Completion

January 1, 2012

Last Updated

November 6, 2012

Record last verified: 2012-11

Locations